Company Overview
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $11.37M (-28.3% YoY); net profit $-6.31M.
- Trailing 12 Months Year-on-year growth — revenue -23.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -7.0%, profit CAGR -38.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -7.02% |
| 1 Year: | -23.20% |
Compounded Profit Growth
| 5 Years: | -38.19% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -99.85% |
| 6 Months: | -99.68% |
| 3 Months: | -99.44% |
| 1 Month: | +0.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.12 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -7.0% CAGR over 5 years.
- Earnings shrank at -38.2% CAGR over 5 years.
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZCMD Zhongchao Inc. | 1.13 | -0.01 | $6.96M | 0.00% | -27.37% | -24.88% | -7.02% | -38.19% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 14.15M | 19.43M | 15.86M | 11.37M |
| Cost of Revenue | - | 7.79M | 10.92M | 6.95M | 6.25M |
| Gross Profit | - | 6.36M | 8.51M | 8.91M | 5.12M |
| Operating Expenses | - | 9.31M | 13.92M | 9.25M | 11.31M |
| Operating Income | - | -2.95M | -5.41M | -341.27K | -6.19M |
| EBITDA | - | -2.22M | -4.49M | 87.09K | -5.87M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -2.55M | -11.98M | 61.76K | -5.77M |
| Tax Provision | - | 272.31K | -669.76K | 335.17K | 46.18K |
| Net Income | - | -2.94M | -11.34M | -643.23K | -6.31M |
| Diluted EPS | 71.42 | -841.46 | -3,239.19 | -92.07 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 38.61M | 24.42M | 25.88M | 24.15M |
| Current Assets | - | 22.70M | 18.71M | 18.71M | 16.96M |
| Cash & Equivalents | - | 11.52M | 7.55M | 7.84M | 8.10M |
| Inventory | - | 189.11K | 592.38K | 586.22K | 0 |
| Receivables | - | 6.77M | 2.55M | 4.68M | 2.78M |
| Total Liabilities | - | 5.60M | 3.38M | 1.73M | 1.55M |
| Current Liabilities | - | 4.17M | 2.68M | 1.53M | 1.53M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.70M | 808.16K | 57.52K | 26.08K |
| Total Equity | - | 29.93M | 18.01M | 20.84M | 18.63M |
| Shares Outstanding | - | 3.32K | 3.32K | 33.94K | 41.34K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -661.74K | 54.23K | -1.47M | 845.39K |
| Investing Cash Flow | - | -3.35M | -3.75M | -1.81M | -826.60K |
| Financing Cash Flow | - | 1.85M | 0 | 3.84M | 0 |
| Capital Expenditure | - | -1.86M | -839.74K | -3.05M | -152.56K |
| Free Cash Flow | - | -2.52M | -785.51K | -4.52M | 692.83K |
| Net Change in Cash | - | -2.16M | -3.70M | 557.20K | 18.79K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 44.9% | 43.8% | 56.2% | 45.0% |
| Operating Margin % | - | -20.9% | -27.8% | -2.2% | -54.4% |
| Net Margin % | - | -20.8% | -58.3% | -4.1% | -55.5% |
| ROE % | - | -9.8% | -63.0% | -3.1% | -33.9% |
| ROCE % | - | -8.6% | -24.9% | -1.4% | -27.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Xtx Topco Ltd | 0.01% | 383 | $432 |
| 2 | Tower Research Capital LLC (TRC) | - | 4 | $4 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZCMD
ZCMD — Frequently Asked Questions
What is the current share price of Zhongchao Inc. (ZCMD)?
As of 2026-08-02 19:16 PDT, Zhongchao Inc. (ZCMD) trades at $1.13 on NasdaqCM. Its 52-week range is $0.95 to $930.00.
What is the market capitalisation of ZCMD?
Zhongchao Inc. (ZCMD) has a market capitalisation of $6.96M on NasdaqCM.
What is the P/E ratio of ZCMD?
ZCMD trades at a trailing price-to-earnings (P/E) ratio of -0.01. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.18.
What is the return on equity (ROE) of ZCMD?
ZCMD has a return on equity (ROE) of -24.88%. Its return on capital employed (ROCE) is -27.37%.
Is ZCMD a good stock to buy?
This page provides a data-driven analysis of Zhongchao Inc. (ZCMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.